Methylcytosine Dioxygenase (TET2) Antibody

Background

TET2 is a member of the TET family of dioxygenases that catalyzes the conversion of 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) in DNA, promoting active DNA demethylation and epigenetic regulation. TET2 is widely expressed in hematopoietic cells and plays a critical role in stem cell self-renewal, differentiation, and lineage commitment. It acts as a tumor suppressor by maintaining genomic stability and ensuring proper gene expression patterns, particularly in hematopoiesis. Loss-of-function mutations in TET2 are frequently observed in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and other hematological malignancies, where they disrupt DNA methylation balance, alter gene regulation, and promote uncontrolled proliferation. TET2 also regulates immune responses by modulating T cell differentiation and inflammatory gene expression. Knockout studies in mice demonstrate enhanced hematopoietic stem cell self-renewal, impaired differentiation, and increased susceptibility to leukemogenesis, emphasizing TET2's role in DNA methylation dynamics, tumor suppression, and immune regulation.